



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Ibrexafungerp

Cat. No.:	HY-107126
CAS No.:	1207753-03-4
Molecular Formula:	C ₄₄ H ₆₇ N ₅ O ₄
Molecular Weight:	730.03
Target:	Fungal
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Ibrexafungerp (MK 3118) is an orally active β -1,3-glucan synthesis inhibitor, with potential antifungal activity. Ibrexafungerp can be used for research of <i>Candida</i> and <i>Aspergillus</i> infections ^[1] .
In Vitro	Ibrexafungerp leads to fungicidal activity against various <i>Candida</i> spp., with MIC of 0.5 μ g/mL ^[2] . Ibrexafungerp is effective against <i>C. albicans</i> , <i>C. krusei</i> , <i>C. parapsilosis</i> with MICs of 0.06, 0.5, 0.25 μ g/mL ^[5] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Ibrexafungerp (p.o., 10 mg/kg) is effective against <i>C. auris</i> in an guinea pig cutaneous infection model ^[4] . Ibrexafungerp (p.o., mouse 1 mg/kg, rat 5 mg/kg and dog 5 mg/kg) exhibits oral bioavailability (mouse 51%, rat 45%, dog 35%) ^[3] . Ibrexafungerp (i.v., mouse 1 mg/kg, rat 5 mg/kg and dog 5 mg/kg) exhibits moderate half-lives (mouse 5.5, rat 8.7 and dog 9.3 h) due to high plasma clearance (0.68, 0.44, and 0.45 L/h/kg respectively) ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:	Guinea pig cutaneous infection model (<i>C. auris</i>) ^[3]
Dosage:	10 mg/kg
Administration:	Oral administration.
Result:	Reduced the severity of lesions and significantly reduced the <i>C. auris</i> fungal burden.

REFERENCES

- [1]. James M Apgar, et al. Ibrexafungerp: An orally active β -1,3-glucan synthesis inhibitor. *Bioorg Med Chem Lett*. 2021 Jan 15;32:127661.
- [2]. Mahmoud Ghannoum, et al. Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of *Candida auris* Infections. *Antibiotics (Basel)*. 2020 Aug 25;9(9):539.
- [3]. Stephen A Wring, et al. Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis. *Antimicrob Agents Chemother*. 2017 Mar 24;61(4):e02068-16.
- [4]. Ghannoum M, et al. Efficacy of Ibrexafungerp (SCY-078) against *Candida auris* in an In Vivo Guinea Pig Cutaneous Infection Model. *Antimicrob Agents Chemother*. 2020

[5]. Arendrup MC, et al. In Vitro Activity of Ibrexafungerp (SCY-078) against *Candida auris* Isolates as Determined by EUCAST Methodology and Comparison with Activity against *C. albicans* and *C. glabrata* and with the Activities of Six Comparator Agents. *Antimicrob Agents Chemother.* 2020 Feb 21;64(3):e02136-19.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA